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A B S T R A C T
Macular edema along with macular ischemia is responsible for decreased visual acuity in central retinal vein occlu-
sion. Bevacizumab (Avastin, Genentech) blocks vascular endothelial growth factor (VEGF) induced hyperpermeability of
blood vessels. In this prospective case series we investigated the efficacy of anti-VEGF treatment in reduction of central
retinal thickness (CRT) and improvement in visual acuity (VA). 25 patients were followed up for 12 months and treated
monthly with intravitreal bevacizumab. VA and CRT were measured at each visit. Treatment was discontinued as the
peak improvement of either parameter was reached and reinstituted in case of deterioration/recurrence of edema. Study
endpoints included: VA using ETDRS charts, CRT and number of injections at 12 months. Mean VA from all 25 patients
increased by 3.1logMAR lines (p<0.05 compared to baseline). The improvement of VA after bevacizumab injection was in
correlation with a decrease in CRT. In subgroup analyses, patients receiving bevacizumab injection within the first 3
months after CRVO showed an average VA gain of 4.2 logMAR lines. Mean of 4.5 injections was needed to control the
disease during the follow-up period. Bevacizumab treatment was effective in VA and reducing CRT. It appears from sub-
group analysis that initiation of treatment early in the course of disease produced better functional outcome. Several in-
jections were needed to control the disease. Regular OCT examinations and retreatment are advised in order to maintain
initially reached VA.
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Introduction
Central retinal vein occlusion (CRVO) is a retinal vas-
cular condition that may cause significant ocular morbid-
ity. It is the second most common retinal vascular disor-
der, after diabetic retinopathy, affecting men and women
equally and occuring predominantly after the age of 65.
The prevalence of CRVO is estimated to be 0.1 to 0.4% in
general population1,2, but both incidence and prevalence
increases with age. CRVO is usually unilateral disease,
but up to 7% of patients may develop any form of retinal
vascular occlusion in the fellow eye within 5 years from
the onset of occlusion in the first eye3–5.CRVO has been
associated with various systemic and ocular pathologic
conditions including : hypertension, diabetes mellitus,
cardiovascular disorders, bleeding and clothing disor-
ders, vasculitis, autoimmune disorders, use of oral con-
traceptives, closed-head trauma, alcohol consumption,
primary open- angle or angle-closure glaucoma. CRVO
can be divided into 2 clinical types: ischemic and non-
ischemic. A number of patients may have an interme-
diate form at presentation with variable clinical course.
Initially, it may be difficult to classify a given patient into
either category, since CRVO may change with time. Non-
ischemic CRVO is the less severe form of the disease. It
may present with good vision, fewer retinal hemorrhages
and cotton-wool spots, no relative afferent pupillary de-
fect, and good retinal perfusion. Nonischemic CRVO may
resolve fully with good visual outcome or may progress to
the ischemic type. Ischemic CRVO is the severe form of
the disease. CRVO may present initially as the ischemic
type, or it may progress from nonischemic. Usually, is-
chemic CRVO presents with severe visual loss, extensive
retinal hemorrhages and cotton-wool spots, presence of
relative afferent pupillary defect, poor retinal perfusion
and a presence of severe electroretinographic changes. In
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addition, patients may end up with neovascular glau-
coma and a painful blind eye. The pathogenesis of CRVO
is not clearly understood. Histopathologic studies of eyes
with CRVO demonstrated a thrombus occluding the lu-
men of central retinal vein at the level of lamina cri-
brosa6. It seems that anatomic abnormalities at the level
of lamina cribrosa may be responsible for development of
CRVO (compression of central retinal vein due to raised
intraocular pressure, atherosclerotic changes in central
retinal artery, or inflammation of the central retinal ar-
tery). Also hemodynamic changes (reduced blood flow, in-
creased blood viscosity, altered lumen wall) may produce
stagnant flow and subsequent thrombus formation in
the central retinal vein. Macular edema along with ma-
cular ischemia is responsible for decreased visual acuity
in central retinal vein occlusion. Bevacizumab (Avastin,
Genentech) blocks vascular endothelial growth factor
(VEGF) induced hyperpermeability of blood vessels. In
this prospective case series we investigated the efficacy
of anti-VEGF treatment in reduction of central retinal
thickness (CRT) and improvement in visual acuity (VA).
Materials and methods
25 patients were followed up for 12 months and
treated monthly with intravitreal bevacizumab. On each
examination we performed slit lamp biomicroscopy to
check any anterior segment abnormalities (iris neovas-
cularization) and fundus examination was performed us-
ing non contact lens biomicroscopy. Visual acuity was
tested (VA) using early treatment diabetic retinopathy
study (ETDRS) chart and central retinal thickness
(CRT) using Optopol SOCT 3D spectral domain optical
coherence tomography (OCT). VA and OCT were mea-
sured at each visit. Also at initial examination we per-
formed fluorescein angiography to each patient. Treat-
ment was discontinued as the peak improvement of
either parameter was reached and reinstituted in case of
deterioration/recurrence of edema. Study endpoints in-
cluded: mean VA (logMAR), mean CRT and mean num-
ber of injections at 12 months. All intravitreal injections
were performed under sterile conditions in the operating
room. Bevacizumab was injected via the pars plana using
30 gauge needle. Then the results were compared to
baseline values and statistically analyzed to see whether
there is a significant change in VA and CRT when com-
pared to baseline values.
Statistical analysis.
The data was analyzed by using nonparametric stu-
dent t-test to determine significance between means.
The data was considered statistically significant for p<
0.05.
Results
At 12 months follow-up visit the mean baseline VA in-
creased by 3.1 lines from 1.03 logMar to 0.72 logMAR (12
months). At the same time mean CRT decreased from
560 microns to 259 microns. In sub-group analysis, pa-
tients receiving bevacizumab injections within the first 3
months after the onset of CRVO showed the greatest vi-
sual recovery gaining an average of 4.2 logMAR units.
Mean of 4.5 injections was needed to control the dis-
ease during the follow-up period. After 12 months of fol-
low-up no severe ocular (endophtalmitis, retinal detach-
ment, uveitis) or systemic adverse events were noticed.
No patient developed disc, iris or retinal neovascula-
rization.
Discussion
Central retinal vein occlusion is the 2nd most common
retinal vascular disorder affecting both men and women,
causing irreversible loss of visual function. Up to now
there is no clear algorithm how to manage the patients
with this disease. Central retinal vein occlusion study
(CVOS), wich was a large, multicentric, prospective, and
randomised study concluded that panretinal photocoa-
gulation was to be performed only in case of ocular
neovascularization (NVD, NVE, iris neovascularization)
could be detected. The study also reported there is no
benefit of grid laser photocoagulation in treatment of
macular edema in eyes with VA 20/50 or worse as there
was no significant difference in mean visual acuity be-
tween treated and untreated eyes. This means that laser
could not improve visual acuity (resolve macular edema),
but only stabilize or induce regression of neovasculariza-
tion3. SCORE study compared efficacy and safety of 1-mg
and 4-mg of intravitreal trimacinolone versus standard
care (observation) for eyes with visual loss associated
with macular edema secondary to CRVO and BRVO. Pa-
tients in the corticosteroid medication groups received
an average of two injections in the first 12 months of the
study. After one year, 27 % of patients in the 1 milligram
group and 26 % of patients in the 4 milligram group expe-
rienced a substantial visual gain of 3 or more lines. Only
7 % of patients in the observation group experienced a
similar visual gain. Therefore, patients in the corticoste-
roid treatment groups were five times more likely to
have a substantial visual gain at one year. However, the
rates of adverse events (particularly elevated intraocular
pressure and cataract) were highest in the 4-mg group.
Occlusion of central retinal vein causes stagnation of the
blood flow and ischemic damage to the retina. Green and
colleagues demonstrated inner retinal ischemic changes
in 25% of eyes enucleated for CRVO. It has been postu-
lated that ischemic damage to the retina increased pro-
duction of vascular endothelial growth factor (VEGF) in
the vitreus cavity, and VEGF has been implicated in the
development of neovascular complications of CRVO
(both anterior, posterior neovascularization and macular
edema.). In a study of enucleated eyes with CRVO and
neovascular glaucoma, intraretinal VEGF production
from areas of ischemic retina was demonstrated7. Also,
aqueous VEGF levels increase prior to the development
of neovascularization of the retina (NVD, NVE, iris neo-
vascularization) and decrease with regression of retinal
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neovascularization after panretinal laser photocoagula-
tion8. VEGF also causes capillary leakage leading to
macular edema, which is the leading cause of visual
cause in both ischemic and nonischemic CRVO. There
are numerous case reports and small studies showing
both efficacy and safety of intravitreal anti-VEGF drugs
(bevacizumab and ranibizumab) in therapy of macular
edema and retinal neovascularization in CRVO. BRAVO
and CRUISE were the first large clinical trials confirm-
ing efficacy of anti-VEGF drugs in CRVO and branch
RVO. BRAVO was a multicenter, randomized, double-
-masked, sham injection-controlled Phase III study of
397 patients designed to assess the safety and efficacy
profile of Lucentis (ranibizumab) in treatment of ma-
cular edema secondary to branch-RVO. 55.2 % of patients
who received 0.3 mg of Lucentis and 61.1 % who received
0.5 mg of Lucentis had their vision improved by 15 let-
ters comparing to 28.8 % of patients receiving sham in-
jections. Mean gain in BCVA was observed beginning at
day seven with a 7.6 and 7.4 letter gain in the 0.3 mg and
0.5 mg study arms of Lucentis, respectively (compared
with 1.9 letters in the sham injection arm).
CRUISE was a multicenter, randomized, double-mas-
ked, sham injection – controlled Phase III study designed
to assess the safety and efficacy profile of Lucentis in
treatment of macular edema secondary to CRVO. The
study includes 392 patients and the results at six months
showed 46.2 % of patients given 0.3 mg of Lucentis and
47.7 % given 0.5 mg of Lucentis improving their vision by
15 letters or more (compared to 16.9 % of patients receiv-
ing sham injections). Mean gain in BCVA was observed
beginning at day seven with an 8.8 and 9.3 letter gain in
the 0.3 mg and 0.5 mg study arms of Lucentis, respec-
tively (compared with 1.1 letters in the sham injection
arm. These studies showed significant improvement
both in VA and resolution of macular edema after anti-
-VEGF therapy. In our case series we administered Ava-
stin (bevacizumab, Genentech) which has the same me-
chanism of action as Lucentis. VA improved by 3.1
logMAR lines and CRT decreased from 560 microns to
256 microns. Mean of 4.5 injections was needed to con-
trol the disease.
These results are consistent with the results descri-
bed in other studies, showing the potential of anti-VEGF
agents not only to stabilize but rather improve func-
tional and anatomical outcome.
As the subgroup analyses showed the best gain in vi-
sual acuity was achieved in patients treated within the
first 3 months after CRVO, we may recommend the ther-
apy to be initiated as early as possible.
Conclusion
Results from our study are compatible with those
from BRAVO and CRUISE trials. We showed that beva-
cizumab appears to be both safe and efficient in improv-
ing VA in patients with central retinal vein occlusion.
Further clinical trials with larger number of patients and
longer follow-up period are needed to confirm efficacy of
bevacizumab in treatment of CRVO.
Abbreviations: CRVO – central retinal vein occlusion,
VEGF – vascular endothelial growth factor, CRT – cen-
tral retinal thickness, VA – visual acuity, ETDRS – early
treatment diabetic retinopathy study, OCT – optical co-
herence tomography, SOCT – spectral domain optical co-
herence tomography, NVD – neovascularization on disc,
NVE – neovascularization elsewhere, CVOS – central
retinal vein occlusion study, BRAVO – branch retinal
vein occlusion study, CRUISE – efficacy and safety of
ranibizumab injections in patients with macular edema
secondary to central retinal vein occlusion, SCORE –
standard care vs. corticosteroid for retinal vein occlusion
study.
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ANTI – VEGF TERAPIJA U LIJE^ENJU OKLUZIJE CENTRALNE RETINALNE VENE
S A @ E T A K
Edem makule te ishemija makule su glavni uzro~nici smanjene vidne o{trine kod okluzije centralne retinalne vene.
Bevacizumab (Avastin, Genentech) blokira vaskularnim endotelnim faktorom rasta (VEGF) induciranu hiperpermea-
bilnost krvnih `ila U ovoj studiji istra`ili smo efikasnost anti – VEGF terapije u redukciji centralne retinalne debljine
(CRT) i pobolj{avanju vidne o{trine(VA).25 pacijenata je pra}eno 12 mjeseci i lije~eno mjese~nim dozama intravitreal-
nog bevacizumaba.VA and CRT su mjereni prilikom svake kontrole. Lije~enje je prekinuto kada je jedan od promatra-
nih kriterija (VA i CRT) maksimalno pobolj{an i ponovo nastavljena prilikom ponovne pojave edema u makuli. Proma-
trani ciljevi studije uklju~ivali su: vidnu o{trinu (VA) mjerenu ETDRS tablicama, centralnu retinalnu debljinu (CRT) i
broj injekcija unutar 12 mjeseci pra}enja. Rezultati su pokazali da je vidna o{trina kod svih 25 pacijenata porasla za 3.1
logMAR reda (p<0.05 prema po~etku). Pobolj{anje vidne o{trine nakon injekcije bevacizumaba bilo je u korealciji sa
smanjenjem CRT. Iz analize podataka vidjelo se da je najve}e pobolj{anje vidne o{trine, koje je iznosilo 4.2 logMAR reda
postignuto unutar prva tri mjeseca nakon okluzije VCR. Tijekom vremena pra}enja od 12 mjeseci bilo je potrebno
prosje~no 4.5 injekcija da bi se postigla kontrola bolesti. Injekcije bevacizumaba pokazale su se efikasne u pobolj{avanju
vidne o{trine i smanjenju centralne retinalne debljine. Tako|er iz analize podataka, ~ini se, da raniji po~etak lije~enja
korelira s boljom krajnom vidnom o{trinom i boljim rezultatima lije~enja.
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